Thursday, February 09, 2012

 
 
 

 
 
 
 
 
Freedom alert: Congress is silently moving to restrict access to dietary supplements
Advertisement
Friday, February 12, 2010
Text Size: increase text size decrease text size

From JBS.org:

New legislation targeting nutritional supplements would considerably broaden the Food and Drug Administration’s (FDA) already expansive regulatory authority by allowing the FDA to impose draconian restrictions on developers, manufacturers, and sellers of nutritional products and on the products themselves.

The misleadingly titled Dietary Supplement Safety Act, introduced by Senator John McCain on February 4 as S. 3002, is a regulatory scheme which would dictate which vitamins, minerals, or herbal products will be permitted for use and in what potency; install an onerous registration system for dietary supplement manufacturers; impose a burdensome documentation process for sellers complete with monetary penalties for non-compliance; and grant sole discretionary powers to the Secretary for immediate product recall.

The very broadly written bill leaves much room for the government to interpret its own definitions for terms like “adulterated,” “misbranded,” and “reasonable probability.” It would even make mandatory the reporting of minor side effects, which is not required for even the worst FDA-approved drugs. A Pandora’s box of intended and unintended legal complications and government harassment of nutritional supplement manufacturers and sellers could very well be unleashed if this bill is passed.

Read full article...

More on the insanity in Washington:

The "Detroitification" of America

Ron Paul: The only way to prevent runaway inflation

What you must know about bankruptcy of the United States

Topics: Government Stupidity | Government | Cruxallaneous
Facebook RSS Feed

 
©2012 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This website may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202.